

# AGS 2015 Updated Beers Criteria

---

Ehab E. Tuppo, DO, MPH, FACOI

ACOI 2016 Annual Convention

# Disclosure Information

ACOI 2016 Annual Convention

- I have no financial relationships to disclose
- I will discuss off label use of medications that will be pointed out during the presentation

# Origins

- Beers MH, Ouslander JG, Rollinger I, et al in 1991
  - **“Explicit Criteria for Determining Inappropriate Medication Use in Nursing Home Residents”**
- In 2011 the updates were taken over by the American Geriatric Society
- Last update published in 2015
  - **“American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults”, J Am Geriatr Soc 63:2227–2246, 2015**



# Purpose of the Beers Criteria

- To identify potentially inappropriate medications that should be avoided in many older adults
  - These have been found to be associated with poor health outcomes, including confusion, falls, and mortality
- To reduce adverse drug events and drug related problems, and to improve medication selection and medication use in older adults

# What's its not for...

- Believing the Criteria judge all uses of the listed drugs to be universally inappropriate
- Be-all and end-all of all potentially inappropriate medications that should be avoided
- Older adults receiving palliative care or are in a hospice setting
- Access to Criteria medications should not be excessively restricted by prior authorization and/or health plan coverage policies

# Key Principles

- **Medications are potentially inappropriate, not definitively inappropriate**
  - Unfavorable balance of benefits and harms for many older adults
  - Are there better alternatives?
  - May still be useful in certain situations
- **Understand why medications are included in the Criteria**
- **Optimal application of Criteria involves offering safer non-pharmacologic and pharmacologic therapies**



# Key Principles

- **The Criteria should be a starting point for identifying and improving medication appropriateness and safety**
  - Captures a small percentage of medication-related problems
  - Works best when used as a starting point to review and discuss a patient's entire medication regimen
  - Addressing medication appropriateness, adherence, and adverse events

# Most Important Principle

- Use clinical common sense
  - The criteria are intended to support, not contradict, common sense and good clinical care



# Anticholinergics

Drugs	Rationale	Recommendation	Alternatives
<b>First-generation antihistamines</b> hydroxyzine, meclizine, promethazine, diphenhydramine	Highly anticholinergic, reduced clearance with age, tolerance, confusion, dry mouth, constipation	Avoid	2 <sup>nd</sup> generation antihistamine (fexofenadine, loratadine), intranasal steroids or normal saline
<b>Antiparkinsonian agents</b> benztropine, trihexyphenidyl	Not recommended for EPS prevention with antipsychotics	Avoid	Carbidopa/levdopa
<b>Antispasmodics</b> atropine, belladonna alkaloids, dicyclomine, hycosamine, scopolamine	Highly anticholinergic, effectiveness is uncertain	Avoid	

# Cardiovascular

Drugs	Rationale	Recommendation	Alternatives
<b>Peripheral <math>\alpha</math>-1 blockers</b> doxazosin, prazosin, terazosin	High risk of orthostatic hypotension, better drugs available	Avoid	Diuretics, ACEI, ARB, LA dihydropyridine CCB
<b>Central alpha blockers</b> clonidine, methyldopa, reserpine	CNS effects, bradycardia, orthostatic hypotension	Avoid clonidine as first line, avoid the rest	
<b>Digoxin</b>	In Afib: $\uparrow$ mortality in HF. $\downarrow$ renal clearance. In HF: Higher doses not beneficial	Avoid as first line	
<b>Nifedipine</b> (immediate release)	Hypotension potential. Risk of myocardial ischemia	Avoid	Long acting dihydropyridine CCB
<b>Amiodarone</b>	$\uparrow$ toxicity than other antiarrhythmics	Avoid as first line unless with HF or LVH	

# Central Nervous System

Drugs	Rationale	Recommendation	Alternatives
<b>Antidepressants and neuropathic pain</b> (tertiary tricyclics) amitriptyline, imipramine, nortriptyline. SSRI-paroxetine	Highly anticholinergic, risk of orthostatic hypotension, sedating	Avoid	SSRI (except paroxetine), SNRI, bupropion. Neuropathic pain: SNRI, capsaicin cream, lidocaine, patch, pregabalin, gabapentin,
<b>Benzodiazepines</b> short & intermediate acting-alprazolam, lorazepam, temazepam	↑ sensitivity, ↓ metabolism, ↑ risk of cognitive decline, falls, MVA, delirium	Avoid	Anxiety: SSRI, SNRI, bupropion
<b>Benzodiazepines</b> long acting-clonazepam, diazepam	REM sleep disorder, ETOH & benzo withdrawal, generalized anxiety disorder	Avoid	For epilepsy: lamotrigine, levetiracetam (Keppra)



# Central Nervous System

Drugs	Rationale	Recommendation	Alternatives
<b>Barbiturates</b> butabarbital, butalbital, mephobarbital	↑ rate of physical dependence, tolerance to sleep benefits, risk of overdose	Avoid	
<b>Nonbenzodiazepine,            benzodiazepine            receptor agonist            hypnotic</b> zolpidem, zaleplon	Similar to benzodiazepines. ↑ hospitalizations & ER visits.	Avoid	
<b>Antipsychotics</b> first (conventional) & second (atypical) generation	↑ rate of cognitive decline & mortality in those with dementia. ↑ CVA risk.	Avoid in dementia & delirium unless other options not effective or patient is a danger to self or others (risperidone, quetiapine).	

# Endocrine

Drugs	Rationale	Recommendation	Alternatives
<b>Androgens</b> testosterone	Contraindicated in prostate ca, potential for cardiac problems	Avoid unless for confirmed hypogonadism with symptoms	
<b>Estrogens</b> with or without progestins	Lack of cardio & cognitive protection. Carcinogenic potential (breast/endometrial)	Avoid unless vaginal cream for dyspareunia, UTIs & other vaginal symptoms	For vasomotor symptoms-SSRI, SNRI, bupropion
<b>Growth hormone</b>	Edema, gynecomastia, arthralgia, impaired fasting glucose	Avoid unless needed for replacement after pituitary gland removal	

# Endocrine

Drugs	Rationale	Recommendation	Alternatives
<b>Insulin</b> (sliding scale)	↑ risk of hypoglycemia	Avoid unless in use with titration of basal insulin	
<b>Sulfonylureas– Long acting</b> chlorpropamide, glyburide	↑ risk of hypoglycemia. Risk of SIADH with Chlorpropamide	Avoid	Short acting-glipizide. Metformin
<b>Medrogestrol</b>	Minimal weight effect. ↑ risk of thrombotic events & death	Avoid	



# Gastrointestinal

Drugs	Rationale	Recommendation	Alternatives
<b>Metoclopramide</b> Reglan	↑ risk of EPS including tardive dyskinesia	Avoid unless for gastroparesis	
<b>Proton Pump Inhibitors</b>	Risk of C-difficile infection, bone loss & fractures	Avoid use for >8 weeks unless high risk (corticosteroids & NSAIDS), Barrett's esophagitis or need for maintenance	
<b>Mineral oil (oral)</b>	Risk of aspiration	Avoid	

# Pain Medications

Drugs	Rationale	Recommendation	Alternatives
<b>Meperidine</b> demerol	Not effective in commonly used doses. ↑ risk of neurotoxicity (delirium) than other opioids	Avoid	Mod-severe pain and chronic pain-tramadol, morphine, oxycodone.
<b>Non-cyclooxygenase-selective NSAIDs</b> Ibuprofen, meloxicam, naproxen, aspirin, etodolac, sulindac	↑ risk of GI bleed/PUD (PPI don't eliminate risk) esp. with increasing age	Avoid chronic use unless alternatives are not effective	
<b>NSAIDs-Indomethacin, ketorolac</b>	Most side effects of NSAIDs. ↑ risk of CNS effects & kidney damage	Avoid	Mild-mod pain-acetaminophen, ibuprofen, naproxen.
<b>Skeletal Muscle relaxants</b> cyclobenzaprine, metaxalone, orphenadrine	↑ risk of anticholinergic effects, sedation, fractures	Avoid	Mild-mod pain-acetaminophen, ibuprofen, naproxen.

# Potentially Important Drug-Drug Interaction

Drug	Interacting drug	Risk	recommendation
ACEIs	Amiloride/triamterene	↑ risk of hyperkalemia	Avoid unless hypokalemia with ACEI
Anticholinergic	Anticholinergic	↑ risk of cognitive decline	Avoid
Antidepressants	≥2 CNS-active drugs	↑ risk of falls	Avoid ≥3 CNS active drugs
Antipsychotics	≥2 CNS-active drugs	↑ risk of falls	Avoid ≥3 CNS active drugs
Corticosteroids	NSAIDS	↑ risk of PUD/GI bleed	Avoid or use GI protection
Lithium	ACEIs, loop diuretics	↑ risk of lithium toxicity	Avoid. Monitor Li levels
Warfarin	Amiodarone, NSAIDS	↑ risk of bleeding	Avoid. Monitor INR
Peripheral α-1 blockers	Loop diuretics	↑ risk of UI in older women	Avoid unless needed
Opioid receptor agonists	≥2 CNS-active drugs	↑ risk of falls	Avoid ≥3 CNS active drugs
Benzodiazepines or hypnotics	≥2 CNS-active drugs	↑ risk of falls and fractures	Avoid ≥3 CNS active drugs



# Take home message

- Potentially inappropriate medications
- Use common sense (clinical)
- Use the Criteria as a starting point for full review of the patient's medications
- Alternatives exist
  - Pharmacological and non-pharmacological
- Watch for drug-drug interactions

Thank you